Cancer Council awards Melanoma Institute Australia researchers funding for ground-breaking cancer research projects
19 March 2019
Almost $9 million of new funding was awarded to 13 ground-breaking cancer research projects at the 2019 Cancer Council NSW Research Awards. The chosen world-class research teams are leading the charge towards a cancer free future by investigating new ways to diagnose and treat the disease.
Melanoma Institute Australia researchers, including Co-Medical Directors Professor Georgina Long and Professor Richard Scolyer, Associate Professor Matteo Carlino and Dr James Wilmott, have been awarded Cancer Council NSW Funding of $425,095 over the 2019-2021 funding period. Dr Wilmott attended the Gala Dinner on Thursday, March 14 to formally accept the grant on behalf of Melanoma Institute Australia.
Melanoma of the skin is the fourth most common cancer in Australia, with over 15,000 people expected to be diagnosed with the disease in 2019. Unlike other cancers of the skin, melanoma can spread throughout the body if not treated early. Termed ‘metastatic melanoma’ this advanced form of the disease kills one Australian every 5 hours.
Once melanoma has spread, the most effective treatment is immunotherapy. These immunotherapies release the brakes on the immune system to attack tumour cells. However, more than 40% of metastatic melanoma patients are not cured with these therapies, more for the other cancers. Therefore doctors need to be able to identify who is or isn’t likely to have benefit from the treatment. This means precious time is lost before alternative treatments are offered to those patients for whom immunotherapy won’t be effective.
Dr Wilmott is part of a team of researchers focused on finding treatments for the more than 40% of patients that are not cured with our best current therapies. In another study funded by Cancer Council NSW early career fellowship, the team of oncologists, pathologists, scientists and statisticians identified a set of immune related genes that are critical for a melanoma patient’s response to immunotherapies. The team have initially used these genes to successfully predict the effectiveness of immunotherapy in 105 patients with advanced melanoma.
In this project, the team aim to translate this information from the laboratory into the clinics of their oncology team, giving them the opportunity to test their methods in over 400 patients. They hope to verify their test can accurately identify patients who will respond to standard immunotherapies and the patients for who should be offered alternative treatment options.
This study could lead to the introduction of a simple test in the earliest stages of treatment planning for patients who are diagnosed with advanced melanoma. This would provide critical information for decision-making and ensure patients are offered the treatments most likely to be effective against their cancer.
This was adapted from the article originally published on Cancer Council NSW.
Join in the fun of the virtual event, and together we can run over melanoma!
Melanoma Institute Australia features prominently in the latest ‘Expertise in Melanoma’ world rankings, released by Expertscape.
Participate in our online survey and help us understand the support needs of melanoma patients and carers.
Clinicians and their patients now have access to three online risk calculators developed by researchers at Melanoma Institute Australia.
MIA's Co-Medical Director Professor Richard Scolyer has received The University of Sydney Alumni Award for International Achievement.
More than 120 MIA clinicians, researchers and staff came together online to share research highlights.
For the 2nd consecutive year, MIA's Co-Medical Director Professor Richard Scolyer has been selected in the top 100 best, brightest, and most powerful advocates of pathology by The Pathologist.
As of Monday 27th July all patients and carers/family members coming into The Poche Centre will be required to bring their own mask.
In a recent issue of Cancer Cell journal, Prof Georgina Long AO and Prof Richard Scolyer discuss the challenge of bringing together clinical work and scientific research to underpin successful cancer research.
Clinicians around the world now have access to a new online calculator that predicts the risk that a patient’s primary melanoma has spread to nearby lymph nodes.
Professor Long has been appointed as an Officer (AO) of the Order of Australia (General Division) for distinguished service to medicine, particularly, to melanoma clinical and translational research, and to professional medical societies.
“I had a complete response within about six months. All of my tumours disappeared."
‘We are extremely proud of our ongoing contribution to the global effort to save lives from melanoma, with Dr Silva’s prestigious award proof that we continue to lead the way,'
MIA's Co-Medical Director, Professor Richard Scolyer, has achieved a Google Scholar h-index of 100.
We know what Melanoma March means to our community, so when we had to cancel our physical events, we created Melanoma March Virtual so that everyone across Australia could still connect to honour loved ones and support each other.
A must-read personal account by Garry Maddox in The Sydney Morning Herald of how immunotherapy is revolutionising melanoma treatment.
On Friday, a publication that lays out the steps needed to find out if a systematic screening program for melanoma would benefit all Australians was published in the Australia & New Zealand Journal of Public Health.
Melanoma March events have been cancelled. A Virtual March will be held on Sunday 29th March. Read this statement from MIA CEO Matthew Browne.
Thank you to the thousands of Aussies who bought ‘Game On Mole‘ t-shirts, took selfies, shared t-shirt pics on social media and started lifesaving conversations around sun safety and skin health.